Enhanced protective response and immuno-adjuvant effects of porcine GM-CSF on DNA vaccination of pigs against Aujeszky’s disease virus

This study was conducted to investigate whether the co-delivery of DNA encoding porcine cytokines would enhance a protective immune response in pigs to a Pseudorabies virus (PRV; or Aujeszky’s disease virus) DNA vaccine. Aujeszky’s disease in pigs results in respiratory and nervous symptoms with important economic losses. To evaluate cytokine effects, eukaryotic expression vectors were constructed for porcine GM-CSF, IL-2 and IFN-γ. cDNA for each of these cytokines was inserted under the control of a CMV promoter in the pcDNA3 plasmid and cytokine expression was confirmed after DNA transfection in various mammalian cell cultures by bioassays (GM-CSF and IL2) and ELISA (IFN-γ). Pigs were vaccinated by single intramuscular injection with plasmid DNA encoding PRV gB and gD along with various combinations of cytokine plasmid constructs. Pig serum was tested for the production of antibody by isotype specific anti-PRV ELISA. Pigs were then challenged with the highly virulent PRV strain NIA3 on day 21 after vaccination. The survival and growth rate of pigs were monitored for seven days after the viral challenge. The co-administration of GM-CSF plasmid increased the immune response induced by gB and gD PRV DNA vaccine. This immune response was characterized by an earlier appearance of anti-PRV IgG2, a significantly enhanced anti-PRV IgG1 and IgG2 antibody response, a significantly decreased and shortened viral excretion in nasal swabs and an improved protection to the viral challenge. In contrast, the co-administration of porcine IL-2 or IFN-γ had no adjuvant effects. Our results thus demonstrate for the first time that the application of porcine GM-CSF gene in a DNA vaccine formulation can exert immuno-adjuvant and protective effects with single vaccination in the natural host pig against Aujeszky’s disease.     

猪繁殖与呼吸综合征病毒GP3/GP5/M真核表达载体的构建及其体液免疫应答

本试验旨在构建表达猪繁殖与呼吸综合征病毒(PRRSV)GP3、GP5和M蛋白的真核重组质粒。以PRRSV LN株为模板,采用PCR方法扩增出GP3、GP5、M基因片段,将扩增的GP5、M通过Linker序列串联成GP5-M,然后将GP3与GP5-M双酶切后插入pcDNA3.1(+)构建重组质粒pcDNA3.1-GP3-GP5-M,将其转染COS7细胞。PCR鉴定表明重组质粒pcDNA3.1-GP3-GP5-M含有PRRSV GP3、GP5-M基因,间接免疫荧光检测表明GP3、GP5-M蛋白在COS7细胞内获得表达。Western blotting检测证实GP3、GP5、M蛋白获得正确表达,并且所表达的GP3、GP5、M蛋白是融合蛋白。将pcDNA3.1-GP3-GP5-M免疫BALB/c小鼠,首免后2周可检测到特异性PRRSV中和抗体,首免后8周中和抗体效价最高可达1∶32。进一步将pcDNA3.1-GP3-GP5-M免疫断奶仔猪,首免后4周即可产生1∶4～1∶8的中和抗体。本试验成功构建了表达PRRSV GP3、GP5和M融合蛋白的真核重组质粒pcDNA3.1-GP3-GP5-M,中和抗体检测表明pcDNA3.1-GP3-GP5-M具有良好的免疫原性,从而为PRRSV基因工程疫苗的研制奠定基础。     

嵌合型猪圆环病毒（PCV1—2）及PCV2 ORF2真核表达质粒对商品猪的免疫保护

应用本实验室构建的嵌合型猪圆环病毒（PCV1—2）及真核表达质粒pcDNA3．1／V5-His-ORF2作为免疫原免疫母源抗体ELISA效价在0．07～0．60不等的商品猪,9头猪随机分为4组,1组（3头）肌肉注射免疫10^3.5 TCID50的PCV1-2／头,2组（2头）肌肉注射真核表达质粒200μg／头,3组（2头）肌肉注射空载体（pcDNA3．1）200μg／头,4组（2头）不免疫作为攻毒对照组。于免疫后42d,PCV1—2组及真核表达质粒组产生了PCV2抗体。免疫后42d所有组攻毒PCV2和PRRSV,剂量分别为2×10^4.5 TCID50／头和10^6 TCID50／头。攻毒后21d,攻毒对照组猪淋巴结比免疫组显著肿大,免疫组猪血清、淋巴结中PCV2病毒栽量低于对照组,攻毒对照组猪淋巴结中PCV2抗原含量高于免疫组。这些结果表明,嵌合型PCV1-2及真核表达质粒肌肉注射免疫商品猪后,对PCV2感染能产生保护性免疫应答,有可能成为候选疫苗。     

Improved immune responses against avian influenza virus following oral vaccination of chickens with HA DNA vaccine using attenuated Salmonella typhimurium as carrier

This study evaluates the immune responses of single avian influenza virus (AIV) HA DNA vaccine immunization using attenuated Salmonella enterica sv. Typhimurium as an oral vaccine carrier and intramuscular (IM) DNA injection. One-day-old specific-pathogen-free (SPF) chicks immunized once by oral gavage with 10(9) Salmonella colony-forming units containing plasmid expression vector encoding the HA gene of A/Ck/Malaysia/5858/04 (H5N1) (pcDNA3.1.H5) did not show any clinical manifestations. Serum hemagglutination inhibition (HI) titer samples collected from the IM immunized chickens were low compared to those immunized with S. typhimurium.pcDNA3.1.H5. The highest average antibody titers were detected on day 35 post immunization for both IM and S. typhimurium.pcDNA3.1.H5 immunized groups, at 4.0±2.8 and 51.2±7.5, respectively. S. typhimurium.pcDNA3.1.H5 also elicited both CD4(+) and CD8(+) T cells from peripheral blood mononuclear cells (PBMCs) of immunized chickens as early as day 14 after immunization, at 20.5±2.0 and 22.9±1.9%, respectively. Meanwhile, the CD4(+) and CD8(+) T cells in chickens vaccinated intramuscularly were low at 5.9±0.9 and 8.5±1.3%, respectively. Immunization of chickens with S. typhimurium.pcDNA3.1.H5 enhanced IL-1β, IL-12β, IL-15 and IL-18 expressions in spleen although no significant differences were recorded in chickens vaccinated via IM and orally with S. typhimurium and S. typhimurium.pcDNA3.1. Hence, single oral administrations of the attenuated S. typhimurium containing pcDNA3.1.H5 showed antibody, T cell and Th1-like cytokine responses against AIV in chickens. Whether the T cell response induced by vaccination is virus-specific and whether vaccination protects against AIV infection requires further study.     

口蹄疫病毒多基因及猪α干扰素共表达载体的构建及其免疫豚鼠效果研究

为探讨口蹄疫病毒多基因及猪α干扰素（IFN-α）基因共表达真核质粒进入临床试验的可行性,本试验用PCR方法扩增了口蹄疫病毒P12A3C及部分2B基因（P12X3C）和猪IFN-α基因,克隆到真核表达载体pBudCE4.1中,经双酶切鉴定后,将重组质粒pBudCE4.1-P12X3C-IFN-α转染BHK-21细胞中,观察目的基因的表达,并将重组质粒免疫豚鼠,检测豚鼠的血清抗体水平、中和抗体滴度及T淋巴细胞增殖情况。结果显示,经酶切鉴定及DNA序列分析成功构建了重组质粒pBudCE4.1-P12X3C-IFN-α,转染BHK-21细胞后,通过Western blotting、间接免疫荧光试验鉴定证实重组质粒能有效表达。ELISA结果显示,重组质粒pBudCE4.1-P12X3C-IFN-α比重组质粒pBudCE4.1-P12X3C能诱导机体产生更高水平的抗口蹄疫病毒的血清抗体,且中和抗体滴度也高于重组质粒pBudCE4.1-P12X3C组。MTT法检测结果表明,重组质粒pBudCE4.1-P12X3C-IFN-α组淋巴细胞增殖可达15%,而重组质粒pBudCE4.1-P12X3C组则为11%。攻毒后重组质粒pBudCE4.1-P12X3C-IFN-α组和灭活疫苗组保护率达100%,高于重组质粒pBudCE4.1-P12X3C组的80%。本试验成功构建了重组质粒pBudCE4.1-P12X3C-IFN-α,猪IFN-α作为佐剂可有效辅助口蹄疫DNA疫苗提高动物体内的免疫反应。     

Effects of porcine reproductive and respiratory syndrome vaccination in breeding-age animals

Little is known about the safety and efficacy of extra-label use of the modified live porcine reproductive-and-respiratory syndrome (PRRS) virus vaccine in gestating sows. Our purpose was to determine the impact of vaccination on reproductive performance in 54 herds in Ontario, Manitoba (Canada) and the mid-western United States that were PRRS-positive, PRRS-negative, or concurrently affected by an outbreak of PRRS when initially vaccinated. Majority-vaccinated herds vaccinated ≥50% but <100% of sows at one time, and limit-vaccinated herds vaccinated <50% of sows at one time. Most majority-vaccinated herds did not vaccinate sows in late gestation, and none vaccinated during the initial PRRS outbreak. Numbers of pigs born alive and weaned decreased when pregnant sows were vaccinated. The effect of vaccination on productivity in the gestation following vaccination depended on the vaccination protocol.     

广西德保县黑猪主要疫病病原学和血清学检测

为了解德保黑猪主要疫病流行状况和免疫效果,2018—2020年釆集166个德保黑猪饲养场点的300份病死猪样品进行非洲猪瘟(ASF)、猪瘟(CSF)、口蹄疫(FMD)、猪繁殖与呼吸综合征(PRRS)、猪伪狂犬病(PR)、猪圆环病毒病(PCV-2)、猪支原体病(PPLO)、猪传染性胸膜肺炎(PCP)、猪链球菌病(SS)、...     

The DNA vaccine vector pcDNA3 induces IFN-alpha production in pigs

The cytokine inducing capacity of the vaccine vector pcDNA3, a methylated form of the plasmid, and pcDNA3 encoding porcine interleukin (IL)-6 or granulocyte/macrophage colony-stimulating factor (GM-CSF) was studied in pigs, using a model with tissue chambers implanted subcutaneously. The production of interferon (IFN)-alpha, IFN-gamma, IL-6 and GM-CSF was studied at local (tissue chamber fluid (TCF)) and systemic (serum) levels during 3 days post-injection. All forms of the plasmid, except the methylated, induced a transient local production of IFN-alpha but no plasmid-induced production of IFN-gamma, GM-CSF or IL-6 could be detected after injection of the plasmids. The IFN-alpha response increased markedly at repeated injections of pcDNA3. This IFN-alpha inducing capacity of the plasmid is likely to affect immune responses at DNA vaccination of pigs.     

The efficacy of FMD vaccine reduced non-structural proteins with a mAb against 3B protein

A monoclonal antibody, 3BIgG, against the prokaryotically expressed foot-and-mouth disease virus (FMDV) non-structural protein (NSP) 3B was obtained. The 3BIgG-sepharose conjugant (3BmAb-6BFF) was prepared by adding the purified 3BIgG into epoxy-activated sepharose 6BFF, incubating with the inactivated FMDV, and then removing the sepharose by centrifugation. The vaccine was made from the supernatant emulsified with oil-adjuvant ISA206. Ten guinea pigs, 26 pigs and six cattle were vaccinated, and a vaccination control group was included without treatment with 3BmAb-6BFF. After 28 days, 9/10 pigs challenged with FMDV were protected, this result was the same as the control group, indicating that the vaccine potency was not reduced after treatment with 3BmAb-6BFF. The other animals were vaccinated weekly for nine weeks, and serum samples were collected to detect 3ABC-antibody titers. The results showed that 3ABC-antibody production was delayed and the positive antibody rates were lower when vaccination was carried out using vaccines treated with 3BmAb-6BFF compared with untreated vaccines. The findings of this study suggest that it is possible to reduce NSPs using a mAb-sepharose conjugant in FMD vaccines without reducing their efficacy.     

Construction of Recombined Plasmid with OmpA Gene of Goat Chlamydophila abortus and Immunogenicity Effect in Mice

To explore the feasibility of entering clinical trials of the goat Chlamydophila abortus eukaryotic plasmids,Chlamydophila abortus OmpA gene was amplified by PCR and cloned into the eukaryotic expressing plasmid pcDNA3.1(+）to construction the recombinant vetor.After identification by PCR and restriction enzyme digestion,this vector was transfected into PK-15 cells and its expression were observed by fluorescent antibody test,the distribution of serum antibodies and plasmid were detected in mice after the immunization of the recombinant vector and molecular adjuvant which was single-stranded DNA of E.coli bacterial genome.The results showed that the recombinant plasmid pcDNA3.1-OmpA was successfully constructed after detecting by PCR,enzyme digestion and sequencing.The OmpA gene was effectively expressed in PK-15 cells.The anti-OmpA antibody levels of the pcDNA3.1-OmpA with molecular adjuvant group was significantly higher than that in pcDNA3.1-OmpA group and the inactivated vaccine group at 14 d after immunization（P<0.05).This levels showed an upward trend following numbers of immunization and times.The highest levels was at 35 d after immunization.Then the antibody titers were gradually decreased which still maintain a higher antibody levels than before.The pcDNA3.1-OmpA could be detected in the heart,liver,spleen,kidney,lung,brain,jejunum and leg muscle of mice on 21 d after immunization,and couldn't be detected in any organs at 49 d after immunization.The results above indicated that the the recombinant vetor based on OmpA gene of Chlamydophila abortus was successfully constructed in this experiment,after joining the molecular adjuvant could induce to a higher level of serum antibodies in mice.     

旋毛虫Ts43基因真核表达载体的构建及其在Vero E6细胞中的表达

利用RT—PCR技术从黑龙江省猪源旋毛虫获得了Ts43基因，并克隆入pcDNA3．1-CT—GFP真核表达载体中构建重组质粒，用该重组质粒在脂质体介导下转染VeroE6细胞，GFP标签证明质粒DNA成功转染到细胞中并得以表达，通过Western—blot分析，细胞裂解液样品中有1条约66ku的条带，可被小鼠旋毛虫阳性血清所识别，与预计大小一致，说明，真核表达载体pcDNA3．1-CT—GFP中的Ts43基因在VeroE6细胞中获得了表达，表达产物具有抗原性。     

A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever

Weaned pigs (6-week-old) and 7-day-old pre-weaned piglets were vaccinated with naked plasmid DNA expressing the gp55/E2 gene from classical swine fever virus (CSFV). Both groups of pigs were then given a booster dose of recombinant porcine adenovirus expressing the gp55 gene (rPAV-gp55). Following challenge with CSFV, 100% of weaned pigs and 75% pre-weaned piglets were protected from disease. Weaned pigs given a single dose of rPAV-gp55 were also protected, but showed a slight increase in temperature immediately post-challenge. However, weaned animals given a DNA prime before rPAV-gp55 showed no fluctuation in body temperature following challenge and no pathology in spleen or lymph nodes upon post-mortem. In addition, no CSFV could be re-isolated from the rPAV vaccinated group and from only one pig in the prime-boost group following challenge, suggesting that both vaccination regimes have the potential to reduce or prevent virus shedding following experimental challenge.     

山羊流产嗜衣原体OmpA基因重组质粒构建及对小鼠免疫效果研究

为探讨山羊流产嗜衣原体重组真核质粒进入临床试验的可行性,本试验用PCR方法扩增出山羊流产嗜衣原体OmpA基因,克隆至真核表达载体pcDNA3.1（+）中,经PCR和双酶切鉴定后,将重组质粒pcDNA3.1-OmpA转染至PK-15细胞,观察目的基因表达情况,并将制备的大肠杆菌基因组单链DNA作为分子佐剂与重组质粒共同免疫小鼠,检测重组质粒在小鼠体内分布情况及血清抗体水平。结果表明,经PCR、双酶切和测序鉴定表明成功构建重组质粒pcDNA3.1-OmpA;转染PK-15细胞后,荧光抗体试验结果证实重组质粒pcDNA3.1-OmpA得到有效表达。首免后14 d,重组质粒加分子佐剂组的抗体效价显著高于重组质粒组和灭活疫苗组（P<0.05）;随着免疫次数增加和时间推移,免疫小鼠抗体水平均呈现上升趋势,至35 d时达到最高峰,此后抗体滴度逐渐下降,但仍维持较高水平。首免后21 d,在小鼠心脏、肝脏、脾脏、肾脏、肺脏、脑、空肠和腿肌中均可检测到质粒的分布,此后逐渐消失,49 d在所检组织中均未检测到重组质粒的存在。表明试验成功构建了基于OmpA基因的山羊流产嗜衣原体重组真核质粒,且加入分子佐剂后可诱导小鼠产生较高水平的血清抗体。     

人血小板生成素基因的克隆及CHO稳定细胞系的建立

 以人肝cDNA为模板克隆了人血小板生成素（Human Thrombopoietin,hTPO）基因,利用基因重组技术构建了带有新霉素抗性基因（neo）筛选标记的pcDNA3.1(+)-hTPO真核表达载体,将重组质粒瞬时转染293T细胞,用鼠抗人TPO 单抗Western blot 检测 TPO蛋白的瞬时表达;再将重组质粒转染中国仓鼠卵巢细胞(Chinese Hamster Ovary,CHO),应用400 μg/mL的G418筛选克隆,经PCR及Western blot验证,获得了3株hTPO蛋白表达水平不同的CHO细胞系,为获得大量蛋白并进行活性功能试验及临床应用奠定基础。     

表达绵羊肺腺瘤病毒跨膜蛋白HepG2细胞系的建立

为深入研究绵羊肺腺瘤病毒(JSRV)与绵羊肺腺瘤病(OPA)发病关系,本研究采用PCR方法从pGEX-4T-1-TM重组质粒中扩增编码JSRV跨膜蛋白(TM)的基因序列,并引入标签多肽HA序列和限制性内切酶位点,将其重组至真核表达载体pcDNA3.1(+)中,构建了重组质粒pcDNA-TM-HA.通过转染HepG2细胞并用G418筛选,对稳定表达TM的阳性细胞进行纯化,获得了稳定表达JSRV tm基因的HepG2细胞系.间接免疫荧光及western blot检测结果表明,重组蛋白TM-HA在HepG2细胞中得到正确表达.JSRV TM蛋白稳定表达细胞系的建立为进一步研究该蛋白与JSRV诱导OPA发病关系提供了重要的实验平台.     

A field evaluation of mortality rate and growth performance in pigs vaccinated against porcine circovirus type 2

OBJECTIVE: To evaluate, under field conditions, the effects of a commercial porcine circovirus type 2 (PCV2) vaccine on mortality rate and growth performance in a herd infected with PCV2 that had a history of porcine circovirus disease. DESIGN: Randomized controlled clinical trial. ANIMALS: 485 commercial, cross-bred, growing pigs. PROCEDURES: Prior to weaning, pigs were randomly assigned within litter to a vaccination or unvaccinated control group. Pigs in the vaccination group were given a commercial PCV2 vaccine at weaning and 3 weeks later. Mortality rate was recorded, and pigs were weighed prior to vaccination, when moved from the nursery, and prior to marketing. Infection status was assessed by serologic testing and detection of viral DNA in serum. RESULTS: Compared with control pigs, pigs vaccinated against PCV2 had a significantly lower mortality rate during the finishing phase, significantly higher average daily gain during the finishing phase, and significantly lower likelihood of being lightweight at the time of marketing. For vaccinated pigs, overall mortality rate was reduced by 50% and average daily gain during the finishing period was increased by 9.3%. At the time of marketing, vaccinated pigs weighed an average of 8.8 kg (19.4 lb) more than control pigs, without any difference in days to marketing. Serum PCV2 antibody titers increased in control pigs, and PCV2 DNA was detected, indicating active PCV2 infection. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggested that vaccination against PCV2 was effective at reducing mortality rate and improving growth performance among pigs in a herd infected with PCV2.     

Antibody response of pigs to inactivated monovalent and bivalent vaccines for porcine parvovirus and pseudorabies virus

Groups of pigs vaccinated with an inactivated bivalent vaccine containing porcine parvovirus (PPV) and pseudorabies virus (PRV) developed geometric mean titers (GMT) of humoral antibody for each of the viruses as high or slightly higher than those of other groups of pigs that were vaccinated with inactivated monovalent vaccines containing one or the other of the same viruses. An increase in GMT after challenge exposure of vaccinated pigs to live virus indicated that vaccination did not prevent virus replication. However, an indication that replication was less extensive in vaccinated pigs was provided by the following. Although neither vaccinated nor nonvaccinated (control) pigs had clinical signs after exposure to the live PPV, the effect of vaccination was evident by the fact that GMT were higher in nonvaccinated pigs after exposure than they were in vaccinated pigs. Conversely, all pigs exposed to live PRV had clinical signs, but these signs varied between mild-to-moderate and transient for vaccinated pigs to severe and fatal for nonvaccinated pigs.     

Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs

Actinobacillus pleuropneumoniae is a causative agent of porcine pleuropneumonia, a highly contagious endemic disease of pigs worldwide, inducing significant economic losses worldwide. Apx toxins, which are correlated with the virulence of A. pleuropneumoniae, were expressed in Saccharomyces cerevisiae and its possible use as an oral vaccine has been confirmed in our previous studies using a murine model. The present study was undertaken to test the hypothesis that oral immunization using S. cerevisiae expressing either ApxI or ApxII could protect pigs against A. pleuropneumoniae as an effective way of inducing both mucosal and systemic immune responses. The surface-displayed ApxIIA#5 expressing S. cerevisiae was selected as an oral vaccine candidate by finding on induction of higher immune responses in mice after oral vaccination. The surface-displayed ApxIIA#5 expressing S. cerevisiae and the ApxIA expressing S. cerevisiae were developed to serve as an oral vaccine in pigs. The vaccinated pigs showed higher specific IgG- and IgA-related antibody activities than the non-treated control and vector control pigs. Additionally, the induced immune responses were found to protect pigs infected with A. pleuropneumoniae according to the analysis of clinical signs and the gross and microscopic pulmonary lesions. These results suggested that the surface-displayed ApxIIA#5 and ApxIA in S. cerevisiae might be a potential oral vaccine to protect pigs against porcine pleuropneumonia. Thus the present study is expected to contribute to the development of a live oral vaccine against porcine pleuropneumonia as an alternative to current conventional vaccines.     

Cross-protection studies between feline infectious peritonitis and porcine transmissible gastroenteritis viruses

Cross-protection studies between the feline infectious peritonitis (FIP) and the porcine transmissible gastroenteritis (TGE) viruses were conducted in cats, pigs and pregnant gilts. Cats vaccinated with TGE virus developed neutralizing antibodies against TGE virus and low titer antibody against FIP virus detected by an indirect fluorescent antibody technique but were not protected against a virulent FIP virus challenge. Baby pigs and pregnant gilts vaccinated with FIP virus did not develop detectable antibodies to TGE virus. Nevertheless, it appeared that vaccination of swine with FIP virus conferred some immunity against TGE virus infection. Seventeen-day-old pigs vaccinated with two doses of FIP virus had a 67% survival rate following a virulent TGE virus challenge, and 75% of the 3-day-old pigs suckling either FIP or TGE-virus-vaccinated gilts survived virulent TGE virus infection in contrast to 0% survival of baby pigs suckling unvaccinated gilts.